Sign in

    Shubhendu Sen Roy

    Research Analyst at Brookline Capital Markets

    Shubhendu Sen Roy is a Research Analyst at Brookline Capital Markets, where he specializes in covering emerging biotechnology and life sciences companies such as SCYNEXIS and Cyclacel Pharmaceuticals. He is recognized for his thoughtful inquiry during earnings calls and maintains a visible presence engaging management of these firms, although publicly available performance metrics and analyst rankings are currently limited. Roy began his career with strong academic credentials, earning a doctorate from the Indian Institute of Science and previously working in research roles including at Arcadia Securities, before joining Brookline Capital Markets. He holds advanced degrees in science but there is no public record confirming FINRA registration or specific securities licenses.

    Shubhendu Sen Roy's questions to SCYNEXIS (SCYX) leadership

    Shubhendu Sen Roy's questions to SCYNEXIS (SCYX) leadership • Q3 2022

    Question

    Shubhendu Sen Roy of Brookline Capital Markets questioned if the increased enrollment in the FURI study would impact financials, how the additional patient data would be utilized, whether certain indications within the FURI trial showed better responses, and asked for the data timeline for the SCYNERGIA study.

    Answer

    President & CEO Dr. Marco Taglietti explained that the incremental cost for additional FURI patients is minimal and the decision was made to maintain strong investigator relationships. Chief Medical Officer Dr. David Angulo stated that all data from FURI and CARES will be analyzed together and compared against external controls to support a salvage therapy indication. He noted that gist infections, like Candida, are expected to show the best response, aligning with the drug's mechanism. Dr. Angulo also confirmed that data from the SCYNERGIA study is expected in the first half of 2023.

    Ask Fintool Equity Research AI